Brief: Eyepoint Announces Topline Results From Lucia, The Second Pivotal Phase 3 Clinical Trial Of Duravyu In Wet AMD

EyePoint

19/10/2026 12:36

Oct 19 (Reuters) - EyePoint Inc EYPT.O:
EYEPOINT ANNOUNCES TOPLINE RESULTS FROM LUCIA, THE SECOND PIVOTAL PHASE 3 CLINICAL TRIAL OF DURAVYU™ IN WET AMD
EYEPOINT - LUCIA TRIAL MET KEY SECONDARY ENDPOINTS INCLUDING 38% REDUCTION IN TREATMENT BURDEN
EYEPOINT - EXPECTS PHASE 3 DME TOPLINE DATA IN Q4 2027
EYEPOINT - DURAVYU DEMONSTRATES CONTINUED FAVORABLE SAFETY PROFILE WITH REDOSING
EYEPOINT - LUCIA PHASE 3 TRIAL DID NOT ACHIEVE PRIMARY ENDPOINT IN WET AMD
EYEPOINT - LUGANO PHASE 3 TRIAL DID NOT MEET PRIMARY ENDPOINT IN WET AMD
EYEPOINT - PHASE 2 VERONA TRIAL IN DME MET PRIMARY ENDPOINT WITH EXTENDED TIME TO SUPPLEMENTAL INJECTION
Source text: ID:nGNXbLq90v
Further company coverage: EYPT.O

 ((Reuters.Briefs@thomsonreuters.com;))